Vivos Therapeutics, Inc. (VVOS) Stock Price & Analysis
Vivos Therapeutics, Inc. (VVOS) rose 0.64% to USD 0.39 as of July 25, 2026 at 06:04 UTC, according to Nexqual real-time market data.
VVOS last closed at USD 0.39; the session ranged USD 0.36–0.41 on volume of 152,612 shares. Market capitalization is $5.46M, with a 52-week range of USD 0.36–5.69 (NCM). Source: Nexqual, July 25, 2026 at 06:04 UTC.
Key Statistics (as of July 25, 2026 at 06:04 UTC)
| Price | USD 0.39 |
|---|---|
| Change | ▲ 0.64% (up) |
| Previous Close | USD 0.39 |
| Open | USD 0.38 |
| Day Range | USD 0.36 – 0.41 |
| 52-Week Range | USD 0.36 – 5.69 |
| Volume | 152,612 shares |
| Market Cap | $5.46M |
| Exchange | NCM |
Technical Analysis (VVOS)
Nexqual's technical model rates VVOS "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 06:04 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 24.57 (oversold) |
| vs SMA50 | Below (USD 0.55) |
| MACD | -0.05 (negative) |
Analyst Ratings (VVOS)
Wall Street analysts rate VVOS "None" based on 3 analysts, with a mean price target of USD 2.12 (range USD 0.75–3.1), per Nexqual as of July 25, 2026 at 06:04 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 2.12 |
| High Target | USD 3.1 |
| Low Target | USD 0.75 |
| Buy / Hold / Sell | 2 / 1 / 0 |
Earnings (VVOS)
| Next Earnings Date | 2026-08-14 |
|---|---|
| EPS Estimate | USD -0.39 |
| Revenue Estimate | $5.80M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.52 vs est -0.45 ▼ miss |
| 2025-12-31 | USD -0.58 vs est -0.48 ▼ miss |
| 2025-09-30 | USD -0.49 vs est -0.51 ▲ beat |
| 2025-06-30 | USD -0.55 vs est -0.38 ▼ miss |
Source: Nexqual, July 25, 2026 at 06:04 UTC.
Financials & Fundamentals (VVOS)
| Total Revenue | $19.57M |
|---|---|
| Revenue Growth (YoY) | +70.50% |
| Gross Margin | +61.79% |
| Operating Margin | -128.67% |
| Profit Margin | -127.70% |
| ROE | -1599.81% |
| Current Ratio | 0.27 |
| Total Cash | $2.11M |
| Total Debt | $12.27M |
| Free Cash Flow | $-10.08M |
Source: Nexqual, July 25, 2026 at 06:04 UTC.
Financial Health Score (VVOS)
Nexqual rates Vivos Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 06:04 UTC.
| Growth | Strong — Revenue +16% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $2M cash vs $12M debt |
| Cash Flow | Weak — FCF negative: -$10M, burning cash |
| Efficiency | Critical — ROE -1600%, ROA -77.7% |
Ownership (VVOS)
| Insider Ownership | +26.35% |
|---|---|
| Institutional Ownership | +13.47% |
| Shares Outstanding | 13.89M |
| Float | 12.13M |
| Short % of Float | +10.82% |
Source: Nexqual, July 25, 2026 at 06:04 UTC.
Leadership (VVOS)
Vivos Therapeutics, Inc. is led by R. Kirk Huntsman (age 67), Co-Founder, Chairman of the Board & CEO, per Nexqual as of July 25, 2026 at 06:04 UTC.
| Co-Founder, Chairman of the Board & CEO | R. Kirk Huntsman (age 67) |
|---|---|
| CFO, Treasurer & Secretary | Bradford K. Amman (age 63) |
| Senior Vice President of Mergers and Acquisition Group | Nicholas M. DeGennaro |
| Executive Assistant to CEO and Chairman & CFO | Jennifer Hauser |
Major Backers & Investors (VVOS)
Notable institutional backers of Vivos Therapeutics, Inc. include Armistice Capital, LLC, Fidelity, Commonwealth Equity Services, LLC, according to Nexqual as of July 25, 2026 at 06:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Armistice Capital, LLC | 8.03% |
| Fidelity | 0.59% |
| Commonwealth Equity Services, LLC | 0.31% |
| IHT Wealth Management, LLC | 0.3% |
| B. Riley Wealth Advisors, Inc. | 0.27% |
| Centurion Wealth Management LLC | 0.26% |
| Xtx Topco Ltd | 0.18% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.16% |
| Geode Capital | 0.69% |
| BlackRock | 0.2% |
Source: Nexqual, July 25, 2026 at 06:04 UTC.
From Vivos Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-04-15)
Key Strengths & Strategy (as disclosed to the SEC)
- Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults.
- It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.
- The company also offers VivoScore Program, a screening and home sleep test in adults and children.
- It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ABVC | ABVC Biopharma, Inc. | USD 1.15 | ▼ 2.54% |
| VRPX | Virpax Pharmaceuticals, Inc. | USD 0 | ▼ 75% |
| RNAZ | TransCode Therapeutics, Inc. | USD 5.93 | ▼ 29.4% |
| TPST | Tempest Therapeutics, Inc. | USD 0.93 | ▼ 2.64% |
| ENSC | Ensysce Biosciences, Inc. | USD 0.26 | ▼ 7.96% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 06:04 UTC. This page is informational and not investment advice.